Zynerba Pharmaceuticals, Inc. appointed Warren Cooper as a Lead Independent Director. In this role, Dr. Cooper, who has served as one of Zynerba's independent directors since August 2015, will act as a key liaison between the Chairman and the independent directors, among other responsibilities Dr. Cooper is a UK-trained physician with more than 35 years of experience in the global pharmaceutical industry. Previously, Dr. Cooper was the CEO of Prism Pharmaceuticals, a venture-backed, specialty pharmaceutical company that he led from inception in September 2004 until the sale of the Company to Baxter International in May 2011.
Zynerba Pharmaceuticals, Inc.
Equities
ZYNE
US98986X1090
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |